Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions

BACKGROUND AND OBJECTIVE: Patients with metastatic anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer (NSCLC) often experience years of disease control on targeted therapies but the disease eventually develops resistance and progresses. Multiple clinical trial efforts to incorporate PD-1/P...

Descripción completa

Detalles Bibliográficos
Autor principal: Schenk, Erin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989807/
https://www.ncbi.nlm.nih.gov/pubmed/36895933
http://dx.doi.org/10.21037/tlcr-22-883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989807/
https://www.ncbi.nlm.nih.gov/pubmed/36895933
http://dx.doi.org/10.21037/tlcr-22-883

Ejemplares similares